Sleep Disorder Market Size & Growth Forecast 2027–2036, By Segments (Disorder Type, End Use, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Sleep Disorder Market size was over USD 32.79 Billion in 2026 and is likely to grow at 10.39% CAGR between 2027 and 2036, crossing USD 88.11 Billion by 2036. The industry revenue for 2027 is calculated at USD 35.68 Billion.

• Base Year Value (2026): USD 32.79 Billion
• CAGR (2027-2036): 10.39%
• Forecast Year Value (2036): USD 88.11 Billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Sleep Disorder Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held 41.15% in 2025, supported by established healthcare infrastructure, specialized sleep centers, strong spending, and broader access to diagnostics and treatment.
  • Asia Pacific is expected to grow fastest as rising awareness, urbanization, lifestyle changes, and improving healthcare access expand demand for specialized sleep disorder services.

• Segment Momentum:

  • Sleep apnea accounted for 51.09% of the market in 2025, supported by increasing awareness of its health risks, broader diagnostic availability, and continuous improvements in screening and treatment options.
  • Diagnostics is the fastest-growing product segment as advances in sleep monitoring systems, wearable devices, and digital health platforms improve early detection and diagnostic accuracy.

• Market Expansion Drivers:

  • Rising prevalence of sleep disorders driving clinical diagnosis and treatment demand
  • Expanding adoption of portable sleep diagnostic and monitoring devices
  • Integration of AI-enabled sleep tracking into consumer wellness ecosystems

• Leading Market Participants:

  Leading companies in the sleep disorder market include ResMed Inc. (United States), Koninklijke Philips N.V. (Netherlands), Fisher & Paykel Healthcare Corporation Limited (New Zealand), Nihon Kohden Corporation (Japan), Natus Medical Incorporated (United States), Drive DeVilbiss Healthcare (United States), BMC Medical Co., Ltd. (China), Oura Health Ltd (Finland), Withings (France), Cadwell Industries, Inc. (United States)

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 32.79 Billion
  • 2027 Estimated Market Size: USD 35.68 Billion
  • Projected Market Size: USD 88.11 Billion by 2036
  • Growth Forecasts: 10.39% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Sleep Apnea (Disorder Type) | Sleep Laboratories and Hospitals (End Use) | Therapeutics (Product)
  • Emerging Opportunity Segment: Insomnia (Disorder Type) | Home Care Settings and Individuals (End Use) | Diagnostics (Product)

Market Growth Drivers and Industry Trends

Rising prevalence of sleep disorders driving clinical diagnosis and treatment demand

Growing awareness of chronic sleep-related conditions, coupled with changing lifestyles, aging populations, and higher rates of stress-related health concerns, is increasing the number of individuals seeking medical evaluation. The sleep disorder market growth is driven by the expanding patient pool requiring diagnostic testing, specialist consultations, and long-term therapeutic interventions for conditions such as insomnia, sleep apnea, restless leg syndrome, and circadian rhythm disorders. Healthcare providers are also placing greater emphasis on early detection because untreated sleep disorders are closely associated with cardiovascular disease, metabolic disorders, mental health conditions, and reduced workplace productivity, encouraging broader use of clinical sleep assessment and evidence-based treatment pathways.

Expanding adoption of portable sleep diagnostic and monitoring devices

Advances in compact diagnostic technologies are enabling sleep assessments to move beyond specialized laboratories into home-based settings, improving patient convenience and expanding access to testing services. By reducing barriers associated with traditional overnight studies, portable monitoring solutions will propel the sleep disorder market growth through faster diagnosis and improved follow-up for patients requiring continuous evaluation. Integration with wireless connectivity, cloud-based reporting, and clinician review platforms also supports ongoing disease management while allowing healthcare systems to optimize clinical resources and reduce waiting times for diagnostic services.

Integration of AI-enabled sleep tracking into consumer wellness ecosystems

Consumer interest in preventive healthcare has encouraged the incorporation of intelligent sleep analytics into wearable devices, smart home technologies, and digital wellness applications. As AI-powered algorithms deliver personalized insights into sleep quality, behavioral patterns, and recovery metrics, the sleep disorder market is benefiting from stronger engagement between consumer wellness platforms and clinical care. Continuous data collection supports earlier recognition of abnormal sleep trends, encourages users to seek professional evaluation when persistent irregularities are detected, and strengthens collaboration between digital health ecosystems and healthcare providers.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence of sleep disorders driving clinical diagnosis and treatment demand	2%	High	North America, Europe	High	Near Term
Expanding adoption of portable sleep diagnostic and monitoring devices	1.8%	Moderate	North America, Asia Pacific	High	Near Term
Integration of AI-enabled sleep tracking into consumer wellness ecosystems	1.5%	Low	North America, Europe	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

In the sleep disorder market, North America held the largest share of 41.15% in 2026, supported by greater awareness of sleep-related health conditions, established healthcare infrastructure, and wider access to diagnostic and treatment services. Increasing recognition of sleep disorders as conditions requiring clinical management is encouraging patients to seek evaluation and long-term care. Strong healthcare spending, availability of specialized sleep centers, and growing adoption of diagnostic technologies are also supporting the region's sustained market presence.

Asia Pacific is expected to register the fastest growth, fueled by rising awareness of sleep health, changing lifestyles, increasing urbanization, and expanding access to healthcare services. Longer working hours, greater exposure to digital devices, and evolving daily routines are contributing to stronger attention toward sleep-related conditions. Improvements in healthcare infrastructure and increasing availability of specialized diagnostic and therapeutic services are further helping extend access to sleep disorder management across the region.

No card data available for this language/report.

Segment Leadership and Growth Trends

 

Disorder Type Segment Analysis: Sleep Apnea (Largest Segment) vs Insomnia (Fastest-Growing Segment)

The sleep apnea disorder type segment led the sleep disorder market, accounting for 51.09% in 2026. Its dominant position was driven by the high prevalence of obstructive sleep disorders, increasing awareness of associated health risks, and greater availability of diagnostic services. Rising recognition of the relationship between sleep apnea and chronic conditions such as cardiovascular disease and metabolic disorders has encouraged earlier diagnosis and treatment. Continuous improvements in screening methods and therapeutic options have also strengthened the segment’s market leadership.

The insomnia disorder type segment is expected to witness the fastest growth over the forecast period due to increasing stress levels, changing lifestyles, and a growing incidence of sleep-related disturbances across different age groups. Greater awareness of the importance of sleep health, expanding access to medical consultation, and the availability of both pharmacological and non-pharmacological treatment options are encouraging more individuals to seek diagnosis and treatment, supporting rapid segment expansion.

End Use Segment Analysis: Sleep Laboratories and Hospitals (Largest Segment) vs Home Care Settings and Individuals (Fastest-Growing Segment)

The sleep laboratories and hospitals end-use segment held the largest share of the sleep disorder market in 2026. Its leadership was supported by the availability of specialized diagnostic equipment, comprehensive patient evaluation, and access to trained healthcare professionals capable of managing complex sleep disorders. Hospitals and dedicated sleep laboratories continue to serve as primary centers for advanced sleep assessments, enabling accurate diagnosis and personalized treatment planning for a wide range of sleep-related conditions.

The home care settings and individuals end-use segment is projected to grow at the fastest pace, driven by increasing adoption of home-based monitoring technologies and convenient treatment solutions. Advances in portable diagnostic devices, remote patient monitoring, and user-friendly therapeutic equipment are enabling patients to manage sleep disorders more comfortably outside traditional clinical environments. Growing preference for accessible and cost-effective care is further supporting the expansion of this segment.

Product Segment Analysis: Therapeutics (Largest Segment) vs Diagnostics (Fastest-Growing Segment)

Holding the largest share of the sleep disorder market, the therapeutics product segment accounted for the dominant position in 2026. Demand was supported by the widespread use of treatment options for managing chronic sleep disorders, including medical devices, behavioral therapies, and prescribed medications. Increasing diagnosis rates and greater emphasis on improving long-term patient outcomes have encouraged broader adoption of therapeutic solutions, reinforcing the segment’s market leadership.

The diagnostics product segment is anticipated to register the fastest growth during the forecast period as healthcare providers place greater emphasis on early detection and accurate assessment of sleep disorders. Technological advancements in sleep monitoring systems, wearable diagnostic devices, and digital health platforms are improving accessibility and diagnostic accuracy. Rising awareness of the importance of timely diagnosis and preventive healthcare is expected to further accelerate demand for diagnostic products.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Disorder Type	Sleep Apnea, Restless Legs Syndrome (RLS), Insomnia, Narcolepsy, Others	Sleep Apnea	Insomnia
End Use	Home Care Settings and Individuals, Sleep Laboratories and Hospitals	Sleep Laboratories and Hospitals	Home Care Settings and Individuals
Product	Diagnostics, Therapeutics	Therapeutics	Diagnostics

Competitive Landscape and Market Positioning

Prominent players in the sleep disorder market:

1. ResMed, Inc. (United States)
2. Koninklijke Philips N.V. (Netherlands)
3. Fisher & Paykel Healthcare Corporation Limited (New Zealand)
4. Nihon Kohden Corporation (Japan)
5. Natus Medical Incorporated (United States)
6. Drive DeVilbiss Healthcare (United States)
7. BMC Medical Co., Ltd. (China)
8. Oura Health Ltd (Finland)
9. Withings (France)
10. Cadwell Industries, Inc. (United States)

Competition in the sleep disorder market is being reshaped by the convergence of diagnostic innovation, personalized treatment approaches, and broader patient monitoring capabilities. Market participants are expanding beyond conventional therapies by incorporating digital assessment tools, connected care models, and more tailored intervention pathways to address diverse sleep-related conditions. The competitive focus is moving toward improving patient engagement and treatment adherence, with providers differentiating through integrated solutions that connect diagnosis, ongoing management, and individualized care strategies.

Industry Development/News

Company Name	Date	Key Development
Eli Lilly and Company	Jun-26	Eli Lilly completed the acquisition of Centessa Pharmaceuticals, integrating a portfolio of orexin receptor 2 agonists targeting narcolepsy and other sleep conditions. This transaction strengthens Eli Lilly's next-generation neuroscience and sleep disorder pipeline through the addition of late-stage clinical assets.
ResMed	Jun-26	ResMed completed the acquisition of Noctrix Health for approximately $340 million. The transaction integrates the FDA-classified Nidra Tonic Motor Activation therapy for refractory moderate-to-severe restless legs syndrome, allowing ResMed to strategically broaden its sleep disorder portfolio beyond traditional obstructive sleep apnea solutions.
Shionogi	Mar-26	Shionogi agreed to acquire Apnimed's stake in their sleep disorder joint venture for $100 million upfront. By taking full control of the entity, Shionogi aims to consolidate its operational footprint and independently accelerate the development of therapeutics targeting sleep disorders.
St. Luke's	Jan-26	St. Luke's expanded its operational sleep laboratory capacity to improve patient access to specialized diagnostics. The expansion scales regional infrastructure for identifying and managing sleep disorders, bringing specialized clinical care closer to its target patient base.
SK biopharmaceuticals	Dec-25	SK biopharmaceuticals and its joint venture partner Ignis Therapeutics secured regulatory approvals in China for solriamfetol. This approval enables geographic expansion of the sleep disorder therapy into a major global central nervous system market.
Lundbeck	Nov-25	Lundbeck submitted a strategic acquisition bid for Avadel Pharmaceuticals. The proposed transaction aims to integrate Avadel's specialized narcolepsy treatment assets, including the sleep disorder therapy Lumryz, into Lundbeck's broader commercial neuroscience and sleep medicine portfolio.
Sunrise	Sep-25	Sunrise raised $29 million in a funding round to accelerate the nationwide scaling of its Dreem Health virtual sleep clinic. The capital injection supports geographic expansion alongside digital innovation in hardware and software for sleep disorder diagnosis.
Apotex	Jan-25	Apotex acquired the U.S. commercial rights to the wakefulness therapies Provigil and Nuvigil. This acquisition expands the company's specialty pharmaceutical portfolio and strengthens its competitive positioning within the commercial sleep-related disorders market.
Harmony Biosciences	Apr-24	Harmony Biosciences acquired Epygenix in a transaction valued at $35 million upfront. This acquisition expands Harmony's neuroscience pipeline and integrates specialized assets that complement its existing commercial presence in the sleep disorder therapeutics segment.
Sanford Health	Feb-22	Sanford Health constructed and opened a new medical clinic in northeast Bismarck, which included the structural relocation of its Sleep Center. The expanded facility enhances delivery and patient access to specialized sleep disorder diagnostic and treatment services.